Ranson, Malcolm R
AffiliationLowe Center for Thoracic Oncology and the Belfer Institute for Applied Cancer Science, Dana-Farber Cancer Institute, Boston
MetadataShow full item record
AbstractThe EGFR T790M mutation is the most common mechanism of drug resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in patients who have lung cancer with an EGFR mutation (EGFR-mutated lung cancer). In preclinical models, the EGFR inhibitor AZD9291 has been shown to be effective against both EGFR tyrosine kinase inhibitor-sensitizing and T790M resistance mutations.
CitationAZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. 2015, 372 (18):1689-99 N Engl J Med
JournalThe New England Journal of Medicine